Extended Data Table 2 Treatment-related AEs by maximum severity in part 1 (phase 1a dose escalation)

From: D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial

  1. aOccurring in ≥15% of patients overall.
  2. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Back to article page